Chemotherapy With or Without Enoxaparin in Pancreatic Cancer
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of chemotherapy with or without enoxaparin. This study is
powered to decrease the DVT/ VTE events rate from 10% to 3% with enoxaparin in the
experimental arm.
N=540pts, dropout-rate 15%, power 80 %, two sided, significant level 5%